Hemostatic compositions and therapeutic regimens

Inventors

Finkielsztein, Sergio • Vournakis, John N

Assignees

Marine Polymer Technologies Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-8871247-B2

Patent

Publication Date

2014-10-28

Expiration Date


Abstract

The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to treat wounds. More specifically the present invention relates to hemostatic compositions that reduce the need for, and cost of, nursing care of patients with chronic wounds by reducing the frequency of wound dressing changes.

Core Innovation

The patent describes a composition comprising biocompatible poly-̂-1→4-N-acetylglucosamine (pGlcNAc) shortened fibers (sNAG), wherein the majority of fibers are less than about 15 ̂m in length and have been irradiated to reduce molecular weight and fiber length while preserving microstructure. The composition is further characterized by increasing the metabolic rate of serum-starved human umbilical cord vein endothelial cells and demonstrating non-reactivity in an intramuscular implantation test.

In mouse wound studies, sNAG accelerates wound closure, reaching 90% closure in under 15 days compared to controls. Reported findings indicate that the composition enhances reepithelialization, proliferation, and neovascularization with no foreign-body response. The material also promotes endothelial-cell migration and modulates angiogenesis-associated markers, while not rescuing serum-starved cells from apoptosis in a trypan blue exclusion test.

Claims Coverage

The patent claim coverage identifies one independent claim comprising three inventive features, along with dependent claims that further refine fiber properties, formulations, and optional components.

Irradiated biocompatible poly-̂-1→4-N-acetylglucosamine fibers

The composition comprises biocompatible poly-̂-1→4-N-acetylglucosamine fibers, wherein the majority of the fibers are less than about 15 ̂m in length and have been irradiated to reduce their length.

Specified endothelial-cell assay characteristics

The composition increases metabolic rate of serum-starved human umbilical cord vein endothelial cells in a MTT assay and/or does not rescue apoptosis of those cells in a trypan blue exclusion test.

Non-reactivity in an intramuscular implantation test

The composition is non-reactive when tested in an intramuscular implantation test.

The independent claim covers irradiated, shortened biocompatible poly-̂-1→4-N-acetylglucosamine fibers possessing specified endothelial-cell assay effects and non-reactivity in an intramuscular implantation test. Dependent claims further define wound-dressing formulations, irradiation conditions, biodegradation timing, and optional growth factors or antimicrobial agents.

Stated Advantages

The composition accelerates wound closure in diabetic-mouse wound studies compared with controls, reaching 90% closure in under 15 days.

The composition enhances reepithelialization, proliferation, and neovascularization with no foreign-body response observed in wound studies.

The composition increases the metabolic rate of serum-starved human umbilical cord vein endothelial cells in a MTT assay.

The composition is non-reactive in an intramuscular implantation test.

Documented Applications

The composition is formulated as a wound dressing, including for chronic, surgical, and burn wounds.

The sNAG membrane is documented in a mouse wound model for wound-healing evaluation, healing-duration comparisons, and wound-area comparisons.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.